Publikationen in Zusammenarbeit mit Forschern von Hospital de la Santa Creu i Sant Pau (52)

2024

  1. Clinical and Epidemiological Characteristics of the 2022 Mpox Outbreak in Spain (CEME-22 Study)

    Open Forum Infectious Diseases, Vol. 11, Núm. 3

  2. Mitochondrial Haplogroups and Weight Gain After Initiating ART in Patients With HIV

    The Journal of infectious diseases, Vol. 230, Núm. 2, pp. 421-425

2023

  1. Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

    International Journal of Infectious Diseases, Vol. 137, pp. 134-143

  2. Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study

    Frontiers in Cellular and Infection Microbiology, Vol. 13

  3. Executive summary of the consensus statement of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), Spanish Society of Neurology (SEN), Spanish Society of Immunology (SEI), Spanish Society of Pediatric Infectology (SEIP), Spanish Society of Rheumatology (SER), and Spanish Academy of Dermatology and Venereology (AEDV), on the diagnosis, treatment and prevention of Lyme borreliosis

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 1, pp. 40-45

  4. Impact of Intermediate Susceptibility to Penicillin on Antimicrobial Treatment and Outcomes of Endocarditis Caused by Viridans and Gallolyticus Group Streptococci

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 77, Núm. 9, pp. 1273-1281

2022

  1. Corrigendum to “Prognosis of unexpected positive intraoperative cultures in arthroplasty revision: A large multicenter cohort” [Journal of Infection 83 (2021) 542–549] (Journal of Infection (2021) 83(5) (542–549), (S0163445321004527), (10.1016/j.jinf.2021.09.001))

    Journal of Infection

  2. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

  3. Outpatient Parenteral Antibiotic Treatment vs Hospitalization for Infective Endocarditis: Validation of the OPAT-GAMES Criteria

    Open Forum Infectious Diseases, Vol. 9, Núm. 9

2021

  1. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

    Journal of Biomedical Science, Vol. 28, Núm. 1

  2. Implant removal in the management of prosthetic joint infection by staphylococcus aureus: Outcome and predictors of failure in a large retrospective multicenter study

    Antibiotics, Vol. 10, Núm. 2, pp. 1-13

  3. Role of asymptomatic bacteriuria on early periprosthetic joint infection after hip hemiarthroplasty. BARIFER randomized clinical trial

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 40, Núm. 11, pp. 2411-2419

2020

  1. Suppressive antibiotic therapy in prosthetic joint infections: a multicentre cohort study

    Clinical Microbiology and Infection, Vol. 26, Núm. 4, pp. 499-505

2019

  1. Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

    Scientific Reports, Vol. 9, Núm. 1

  2. Role of age and comorbidities in mortality of patients with infective endocarditis

    European Journal of Internal Medicine, Vol. 64, pp. 63-71

  3. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

    Antiviral Research, Vol. 170

2018

  1. Dysregulation of the immune system in HIV/HCV-coinfected patients according to liver stiffness status

    Cells, Vol. 7, Núm. 11

  2. Gentamicin may have no effect on mortality of staphylococcal prosthetic valve endocarditis

    Journal of Infection and Chemotherapy, Vol. 24, Núm. 7, pp. 555-562

  3. Human immunodeficiency virus/hepatits C virus coinfection in Spain: Elimination is feasible, but the burden of residual cirrhosis will be significant

    Open Forum Infectious Diseases, Vol. 5, Núm. 1

2017

  1. Dual Therapy with Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy with Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial

    Clinical Infectious Diseases, Vol. 65, Núm. 12, pp. 2112-2118